世界製藥 (2022)

Global Pharmaceutical Tracker, 2022

出版日期: 2022年07月13日 | 出版商:

Frost & Sullivan | 英文 22 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

預計全球製藥市場將通過專注於藥物發現和開發的數字合作夥伴關係推動未來增長。

由於數字化內爆，製藥公司的商業模式正在發生變化，以實現數字化成熟。大型製藥公司正在與技術供應商合作，以加速數字化並降低對內部能力、平台和解決方案的投資風險。研發渠道下降、過去二十年來生產力停滯不前以及大流行導致臨床試驗中斷，導致合作夥伴關係激增。

本報告探討了全球製藥市場，並全面討論了 2022 年的主要製藥行業批准、併購、產品許可交易和數字合作夥伴關係。

內容

執行摘要

主要亮點
製藥行業 - 值得關注的公司

新模式的批准（2022 年第一季度）

批准新模式

併購（2022 年第一季度）

重大併購

關鍵的許可和許可協議（2022 年第一季度）

主要的入許可和出許可協議

關鍵數字合作夥伴（2022 年第一季度）

數字合作
免責聲明

簡介目錄

Product Code: K6F0-50

Digital Partnerships Focused on Drug Discovery and Development Drive Future Growth Potential

This research service offers comprehensive discussions about the key approvals, mergers and acquisitions, product licensing deals, and digital partnerships of the pharmaceutical industry in 2022. A renewed focus on operational excellence and digital transformation will push top-line pharmaceutical industry growth and drive strong partnerships with small and mid-size pharma and digital solution vendors.

The digital implosion is transforming the pharma business model to achieve digital maturity. Big pharma is moving toward technology vendor partnerships to accelerate digitization and de-risk investments in in-house capabilities, platforms, and solutions. Diminishing R&D pipelines, stagnant productivity during the last 2 decades, and the disruption in clinical trials due to the pandemic have led to a surge in partnerships. Small and mid-sized companies will continue to attract big pharma and private equity (PE) firms. New modalities and technologies will remain attractive for licensing deals, giving biotech licensor candidates a higher chance of negotiating contract terms and up-front payments.